Aclaris Therapeutics Stock News

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.41 per share a year ago.

Here is how Aclaris Therapeutics (ACRS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.

Aclaris Therapeutics shares plunged more than 24% Wednesday after the company's mild to severe atopic dermatitis (AD) treatment received disappointing topline results.  The results from the 4-week Ph

Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.

Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as thei

Penny stocks, defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it's understandable why penny stocks attract inter

Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c

Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c

Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.

Aclaris Therapeutics shares fell almost 90% after the biopharmaceutical company announced it is no longer continuing with the development of its rheumatoid arthritis therapeutic zunsemetinib. The comp